May 17, 2016
ISELIN, N.J., May 17, 2016 /PRNewswire/ — Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced the successful technology transfer of its Application Programming Interface (API) and software application (App) to Medical Technologies Innovation Asia (MTIA), Ltd., its strategic partner in China. The new API and App will greatly simplify MTIA’s integration of its own Chinese CGM App.
Significant improvements were made to the API that will simplify the task of writing software applications to access Echo’s glucose information on MTIA’s mobile device. Additionally, Echo developed a proprietary CGM App for MTIA that provides calibrated glucose information. This App will also be used to demonstrate how to develop other Apps using Echo’s API technology.
“This achievement is a major step toward bringing our CGM to a part of the world where a quarter of the diabetes population reside. We look forward to continuing to support MTIA in their efforts to commence the CFDA regulatory trial in China in the near term,” said Scott W. Hollander, Echo’s President and CEO. “With the achievement of this milestone, our development team is now focused on the completion of our NextGen CGM system.”
About Echo Therapeutics
Echo Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) system. A significant opportunity exists for the Company’s CGM to be used in the outpatient diabetes market and in the fitness, weight loss and personal lifestyle wearable-health space. A longer-term opportunity also exists in the hospital settings. Echo developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo’s clinical studies, the safety and efficacy of Echo’s CGM System, the failure of future development and preliminary marketing efforts related to Echo’s CGM System, Echo’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo’s and its partners’ ability to develop, market and sell Echo’s CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its CGM System. These and other risks and uncertainties are identified and described in more detail in Echo’s filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2015, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
SOURCE Echo Therapeutics, Inc.